Maria Eduarda Palomba

Mrs. Maria Eduarda Palomba


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MPMaria Eduarda Palomba
Maria Eduarda Palomba
JKJulia Adriana Kasmirski
Julia Adriana Kasmirski
FHFlavio Hojaij
Flavio Hojaij
Skin cancer is the most common cancer form worldwide, and it is primarily divided into melanoma and non-melanoma types, with non-melanoma being the most prevalent condition. Cutaneous squamous cell carcinoma (cSCC) accounts for 50% of primary skin cancers and is characterized by uncontrolled keratinocyte proliferation. cSCC’s current standard treatment is surgical resection and chemotherapy. Unfortunately, these methods often lead to disfigurement, functional morbiditly, and compromised function. In contrast to immunotherapy, emerging scenarios have shown promising results, especially in neoadjuvant settings. Cemiplimab (Libtayo®; Regeneron, Tarrytown, NY, USA), a PD-1 monoclonal antibody, has shown efficacy in treating advanced or metastatic cSCC, and its use as a neoadjuvant therapy has been recently explored. This review aims to evaluate Cemiplimab in the neoadjuvant setting for cSCC treatment. The Methodology followed PRISMA guidelines, this review analyzed studies on Cemiplimab as a neoadjuvant therapy for cSCC that were sourced from PubMed, Web of Science, and Scopus. Only controlled trials, cohort studies, case series, and systematic reviews were included. From 341 records, 21 studies were included, and six clinical trials provided key data about neoadjuvant Cemiplimab’s response rates, efficacy, adverse effects, and safety considerations. The targeted data revealed a neoadjuvant Cemiplimab mean pathologic response rate of 72%, with a 62% objective response rate. Treatment-related adverse events (TRAEs) affect 66% of patients, though most cases are not severe. The most common include fatigue, maculopapular rash, and diarrhea. The studies showed high rates of complete pathological responses (cPRs) and major pathological responses (mPRs), suggesting a strong therapeutic potential. Neoadjuvant Cemiplimab for cSCC therapy shows high response rates, low recurrence, improved survival, and manageable side effects. The current literature indicates that Cemiplimab may also be effective when used in immunosuppressed patients. Despite more research still being needed to confirm its long-term benefits and the effects of the drug’s use outside of clinical trials, there is strong evidence to consider neoadjuvant Cemiplimab as a promising and efficient treatment.

17 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MPMaria Eduarda Palomba
Maria Eduarda Palomba
FHFlavio Hojaij
Flavio Hojaij
JKJulia Adriana Kasmirski
Julia Adriana Kasmirski
Background/Objectives: Skin cancer is the most common cancer worldwide, primarily divided into melanoma and non-melanoma types, with non-melanoma being the most prevalent. Cutaneous squamous cell carcinoma (cSCC) represents 50% of primary skin cancers and is characterized by uncontrolled keratinocyte proliferation. cSCC current standard treatment is surgical resection and chemotherapy. Unfortunately these methods often lead to disfigurement, functional morbidly and compromised function. In contrast from immunotherapy emerging scenarios that have shown promising results, especially in neoadjuvant settings. Cemiplimab (Libtayo®; Regeneron, Tarrytown, New York, United States), a PD-1 monoclonal antibody, has shown efficacy in treating advanced or metastatic cSCC, and its use as a neoadjuvant therapy has been recently explored. This review aims to evaluate Cemiplimab neoadjuvant setting on cSCC treatment. Methods: Following PRISMA guidelines, this review analyzed studies on Cemiplimab as neoadjuvant therapy for cSCC, sourced from PubMed, Web of Science, and Scopus. Only controlled trials, cohort studies, case series, and systematic reviews were included. A total of 21 studies were examined, focusing on response rates, adverse effects, and outcomes. Results: From 341 records, 21 studies were included, and six clinical trials provided key data.The targeted data revealed that neoadjuvant Cemiplimab showed a mean pathologic response rate of 72%, with a 62% objective response rate. The most commonly found treatment-related adverse events (TRAEs) included fatigue, maculopapular rash, and diarrhea, affecting 66% of patients, with few severe cases. The studies demonstrated high rates of complete pathological responses (cPR) and major pathological responses (mPR), suggesting a strong therapeutic potential. Conclusions: Neoadjuvant Cemiplimab for cSCC therapy shows high response rates, low recurrence, improved survival, and manageable side effects. Despite more research is still needed to confirm its long-term benefits and real-world settings feasibility, some case series already indicate comparable results in immunosuppressed patients. Finally, there is strong evidence to consider neoadjuvant Cemiplimab as a promising and efficient treatment